Use of A2A adenosine receptor agonists

US8106029B2 · kind B2 · utility

Assignee

• Gilead Sciences, Inc. · US

Inventors

• Toufigh Gordi · Sunnyvale, US
• Ann Walls Olmsted · Palo Alto, US
• Hsiao Lieu · Burlingame, US
• Luiz Belardinelli · Palo Alto, US

Key dates

• Filing date: Dec 14, 2009
• Grant date: Jan 31, 2012
• Expiry date: Dec 14, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/0019
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Myocardial imaging methods are provided that are accomplished by administering doses of a pharmaceutical composition comprising one or more adenosine A2A receptor agonists, in particular regadenoson, useful for, among other indications, myocardial imaging and coronary vasodilation, in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.